Daratumumab combo for new AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with a type of AL amyloidosis (a condition where abnormal protein clumps damage organs).
- Your blood tests show a clear difference between your light chain levels (the abnormal proteins).
- Your bone marrow, liver, and kidneys are still working adequately (your doctor will test this).
- You are willing to use contraception (if you could become pregnant or get someone pregnant) during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This study tests whether a new antibody drug called elranatamab can help treat newly diagnosed AL amyloidosis (a disease where abnormal proteins build up in organs). If you haven't had treatment yet and have confirmed AL amyloidosis, this trial may offer access to an experimental therapy.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new investigational drug (etentamig) against a standard combination of four medicines to see which better controls the disease and its symptoms. It is for adults newly diagnosed with AL amyloidosis who have not yet been treated.
Hear when a new Amyloid Light-chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.